Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preclinical models of antipsychotic drug-induced metabolic side effects
Heidi N. Boyda, Lurdes Tse, Ric M. Procyshyn, et al.
Trends in Pharmacological Sciences (2010) Vol. 31, Iss. 10, pp. 484-497
Closed Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
Toby Pillinger, Robert A. McCutcheon, Luke Vano, et al.
The Lancet Psychiatry (2019) Vol. 7, Iss. 1, pp. 64-77
Open Access | Times Cited: 715
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
William J. Panenka, Ric M. Procyshyn, Tania Lecomte, et al.
Drug and Alcohol Dependence (2012) Vol. 129, Iss. 3, pp. 167-179
Closed Access | Times Cited: 392
Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters
Kieran Davey, Siobhain M. O’Mahony, Harriët Schellekens, et al.
Psychopharmacology (2012) Vol. 221, Iss. 1, pp. 155-169
Closed Access | Times Cited: 259
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight
F. Revel, J‐L Moreau, Bruno Pouzet, et al.
Molecular Psychiatry (2012) Vol. 18, Iss. 5, pp. 543-556
Open Access | Times Cited: 258
Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat
Kieran Davey, Paul D. Cotter, Órla O’Sullivan, et al.
Translational Psychiatry (2013) Vol. 3, Iss. 10, pp. e309-e309
Open Access | Times Cited: 220
Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system
Joanne Y.T. Leung, Alasdair M. Barr, Ric M. Procyshyn, et al.
Pharmacology & Therapeutics (2012) Vol. 135, Iss. 2, pp. 113-122
Closed Access | Times Cited: 148
Effects of Antipsychotic Medications on Appetite, Weight, and Insulin Resistance
Chao Deng
Endocrinology and Metabolism Clinics of North America (2013) Vol. 42, Iss. 3, pp. 545-563
Closed Access | Times Cited: 148
Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation
Johan Fernø, Luis Varela, Silje Skrede, et al.
PLoS ONE (2011) Vol. 6, Iss. 6, pp. e20571-e20571
Open Access | Times Cited: 122
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Nina Dedic, Lien Wang, Éva Hajós‐Korcsok, et al.
Molecular Metabolism (2024) Vol. 80, pp. 101883-101883
Open Access | Times Cited: 8
Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor
Katrina Weston‐Green, Xu‐Feng Huang, Chao Deng
CNS Drugs (2013) Vol. 27, Iss. 12, pp. 1069-1080
Closed Access | Times Cited: 94
Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes
Jiezhong Chen, Xu‐Feng Huang, Renfu Shao, et al.
Frontiers in Neuroscience (2017) Vol. 11
Open Access | Times Cited: 77
Acute Effects of Single-Dose Olanzapine on Metabolic, Endocrine, and Inflammatory Markers in Healthy Controls
Margaret Hahn, Tom Wolever, Tamara Arenovich, et al.
Journal of Clinical Psychopharmacology (2013) Vol. 33, Iss. 6, pp. 740-746
Closed Access | Times Cited: 72
Antipsychotics and glucose metabolism: how brain and body collide
Chantel Kowalchuk, L Castellani, Araba Chintoh, et al.
AJP Endocrinology and Metabolism (2018) Vol. 316, Iss. 1, pp. E1-E15
Open Access | Times Cited: 70
Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies
Kyle J. Burghardt, Berhane Seyoum, Abdullah Mallisho, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018) Vol. 83, pp. 55-63
Open Access | Times Cited: 65
<p>Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review</p>
Haiyun Xu, Xiaoyin Zhuang
Neuropsychiatric Disease and Treatment (2019) Vol. Volume 15, pp. 2087-2099
Open Access | Times Cited: 61
A Focused Review of the Metabolic Side-Effects of Clozapine
Jessica W. Y. Yuen, David D. Kim, Ric M. Procyshyn, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 53
Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats
Silje Skrede, Johan Fernø, María J. Vázquez, et al.
The International Journal of Neuropsychopharmacology (2011) Vol. 15, Iss. 2, pp. 163-179
Open Access | Times Cited: 78
Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation?
Emilie Lauressergues, Elodie Bert, Patrick Duriez, et al.
Neuropharmacology (2011) Vol. 62, Iss. 2, pp. 784-796
Closed Access | Times Cited: 71
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats
Heidi N. Boyda, Ric M. Procyshyn, Lurdes Tse, et al.
Journal of Psychiatry and Neuroscience (2012) Vol. 37, Iss. 6, pp. 407-415
Open Access | Times Cited: 55
Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects
Silje Skrede, Luís Martins, Rolf K. Berge, et al.
The International Journal of Neuropsychopharmacology (2013) Vol. 17, Iss. 01, pp. 91-104
Open Access | Times Cited: 52
Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats
Heidi N. Boyda, Alfredo Ramos‐Miguel, Ric M. Procyshyn, et al.
The International Journal of Neuropsychopharmacology (2013) Vol. 17, Iss. 01, pp. 77-90
Open Access | Times Cited: 48
Antipsychotic and Psychostimulant Drug Combination Therapy in Attention Deficit/Hyperactivity and Disruptive Behavior Disorders: A Systematic Review of Efficacy and Tolerability
David Linton, Alasdair M. Barr, William G. Honer, et al.
Current Psychiatry Reports (2013) Vol. 15, Iss. 5
Closed Access | Times Cited: 46
Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia
Hu Yan, Jindong Chen, Xiaoyan Zheng
Psychopharmacology (2013) Vol. 229, Iss. 1, pp. 1-7
Closed Access | Times Cited: 46
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Karla Mayfield, Dan Siskind, Karl Winckel, et al.
Journal of Psychopharmacology (2016) Vol. 30, Iss. 3, pp. 227-236
Closed Access | Times Cited: 43
Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats
Paolo Lazzari, Valeria Serra, S. Marcello, et al.
European Neuropsychopharmacology (2017) Vol. 27, Iss. 7, pp. 667-678
Closed Access | Times Cited: 41
Page 1 - Next Page

Scroll to top